Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors to...
This trade brings opportunity for investors looking for a a company with great fundamentals and nice risk/reward potential into end of year. As the chart shows (blue arrows) I am awaiting a buying opp around the blue trend line. From current stock price, potential risk/reward around 3.5 : 1 downside risk: $1.39 upside reward: $3.50-$5 Recent selloff after...
Nordic Nanovector $NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016. Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his...
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Technicals: Nordic Nanovector retraced from recent high to fill gaps down to support at NOK 48, which triggered a strong reversal pattern. Investors will be keen to follow if the stock establishes a trading range above 53 NOK which would represent a breakout from the recent downtrend, and even more if the stock could possibly break free from the almost two year...
ATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset. ***Any information represented...
After a stellar 2016 (nanoinvestors.wordpress.com), things have been going downhill for the Nordic Nanovector stock. After recently giving a sell signal by crashing through a triple bottom at NOK 68, investors are now looking to the NOK 40 line to see if it can provide support for a bounce.
A few thoughts on CLVS. May not pan out, but this is a bullish scenario. Reasons the bull scenario could play out from a technical standpoint: 1. Move up to $99 was a clear 5 waves. It looks to have recently completed the ABC correction into a perfect golden pocket 61.8 to 65% retracement. 2. Wave C was an ending diagonal. CLVS has broken out of the diagonal...
Blood diagnostic OncoCEE-BR was used by Columbia University College of Physicians and Surgeons in New York City to aid cancer patients' diagnosis. Involved biopsies are no longer required, cancer can be detected with a simple blood test. The chart has strong bullish divergence, has just made a breakout with an initial target around 4 dollars.